JP2017534571A - 抗体3e10の多価フラグメントおよびその使用方法 - Google Patents
抗体3e10の多価フラグメントおよびその使用方法 Download PDFInfo
- Publication number
- JP2017534571A JP2017534571A JP2017511183A JP2017511183A JP2017534571A JP 2017534571 A JP2017534571 A JP 2017534571A JP 2017511183 A JP2017511183 A JP 2017511183A JP 2017511183 A JP2017511183 A JP 2017511183A JP 2017534571 A JP2017534571 A JP 2017534571A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- seq
- binding molecule
- scfv3e10
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043228P | 2014-08-28 | 2014-08-28 | |
| US62/043,228 | 2014-08-28 | ||
| PCT/US2015/047174 WO2016033321A1 (en) | 2014-08-28 | 2015-08-27 | Multivalent fragments of antibody 3e10 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019217791A Division JP2020040987A (ja) | 2014-08-28 | 2019-12-02 | 抗体3e10の多価フラグメントおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017534571A true JP2017534571A (ja) | 2017-11-24 |
| JP2017534571A5 JP2017534571A5 (cg-RX-API-DMAC7.html) | 2018-10-04 |
Family
ID=54064606
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511183A Withdrawn JP2017534571A (ja) | 2014-08-28 | 2015-08-27 | 抗体3e10の多価フラグメントおよびその使用方法 |
| JP2019217791A Withdrawn JP2020040987A (ja) | 2014-08-28 | 2019-12-02 | 抗体3e10の多価フラグメントおよびその使用方法 |
| JP2022001621A Pending JP2022037244A (ja) | 2014-08-28 | 2022-01-07 | 抗体3e10の多価フラグメントおよびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019217791A Withdrawn JP2020040987A (ja) | 2014-08-28 | 2019-12-02 | 抗体3e10の多価フラグメントおよびその使用方法 |
| JP2022001621A Pending JP2022037244A (ja) | 2014-08-28 | 2022-01-07 | 抗体3e10の多価フラグメントおよびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20170291961A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3194450A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2017534571A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016033321A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021534788A (ja) * | 2018-08-31 | 2021-12-16 | イェール ユニバーシティーYale University | 三重鎖およびヌクレアーゼベースの遺伝子編集を亢進するための組成物および方法 |
| JP2022500009A (ja) * | 2018-08-31 | 2022-01-04 | イェール ユニバーシティーYale University | ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6178785B2 (ja) | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーYale University | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
| WO2015134607A1 (en) | 2014-03-04 | 2015-09-11 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations |
| US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
| US12486318B2 (en) | 2016-06-15 | 2025-12-02 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| EP3471777A1 (en) * | 2016-06-15 | 2019-04-24 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| US11613590B2 (en) * | 2017-07-17 | 2023-03-28 | Nucleus Therapeutics Pty. Ltd | Binding proteins 1 |
| US20210137960A1 (en) | 2018-02-01 | 2021-05-13 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
| US12304970B2 (en) | 2018-02-01 | 2025-05-20 | Yale University | Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus |
| US20210340279A1 (en) * | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| KR20220101073A (ko) | 2019-08-30 | 2022-07-19 | 예일 유니버시티 | 핵산을 세포로 전달하기 위한 조성물 및 방법 |
| WO2021077070A1 (en) | 2019-10-18 | 2021-04-22 | Yale University | Compositions and methods for inhibition of cell-penetrating antibodies |
| WO2022047424A1 (en) | 2020-08-31 | 2022-03-03 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| AU2023228912A1 (en) | 2022-03-03 | 2024-09-19 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
| EP4584292A1 (en) | 2022-09-09 | 2025-07-16 | Yale University | Proteolysis targeting antibodies and methods of use thereof |
| WO2024140936A1 (en) * | 2022-12-30 | 2024-07-04 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Humanized cell-penetrating antibodies |
| WO2026039779A1 (en) | 2024-08-15 | 2026-02-19 | Yale University | Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000507225A (ja) * | 1996-03-08 | 2000-06-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | mab 3E10 ならびにその突然変異体および/または機能性フラグメントを使用する送達システム |
| JP2014513069A (ja) * | 2011-04-01 | 2014-05-29 | イェール ユニバーシティー | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4812397A (en) | 1987-02-10 | 1989-03-14 | The Regents Of The University Of California | MAB-anti-DNA related to nephritis |
| WO2012145125A1 (en) * | 2011-03-25 | 2012-10-26 | 4S3 Bioscience Inc. | Targeted radionuclides |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
-
2015
- 2015-08-27 JP JP2017511183A patent/JP2017534571A/ja not_active Withdrawn
- 2015-08-27 EP EP15760023.0A patent/EP3194450A1/en not_active Withdrawn
- 2015-08-27 US US15/507,324 patent/US20170291961A1/en not_active Abandoned
- 2015-08-27 WO PCT/US2015/047174 patent/WO2016033321A1/en not_active Ceased
-
2019
- 2019-11-06 US US16/676,076 patent/US20200199255A1/en not_active Abandoned
- 2019-12-02 JP JP2019217791A patent/JP2020040987A/ja not_active Withdrawn
-
2022
- 2022-01-07 JP JP2022001621A patent/JP2022037244A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000507225A (ja) * | 1996-03-08 | 2000-06-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | mab 3E10 ならびにその突然変異体および/または機能性フラグメントを使用する送達システム |
| JP2014513069A (ja) * | 2011-04-01 | 2014-05-29 | イェール ユニバーシティー | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021534788A (ja) * | 2018-08-31 | 2021-12-16 | イェール ユニバーシティーYale University | 三重鎖およびヌクレアーゼベースの遺伝子編集を亢進するための組成物および方法 |
| JP2022500009A (ja) * | 2018-08-31 | 2022-01-04 | イェール ユニバーシティーYale University | ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法 |
| JP7570107B2 (ja) | 2018-08-31 | 2024-10-21 | イェール ユニバーシティー | ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法 |
| JP7570106B2 (ja) | 2018-08-31 | 2024-10-21 | イェール ユニバーシティー | 三重鎖およびヌクレアーゼベースの遺伝子編集を亢進するための組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016033321A1 (en) | 2016-03-03 |
| US20170291961A1 (en) | 2017-10-12 |
| US20200199255A1 (en) | 2020-06-25 |
| JP2022037244A (ja) | 2022-03-08 |
| JP2020040987A (ja) | 2020-03-19 |
| EP3194450A1 (en) | 2017-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022037244A (ja) | 抗体3e10の多価フラグメントおよびその使用方法 | |
| US10238742B2 (en) | Cell penetrating nucleolytic antibody based cancer therapy | |
| US10040867B2 (en) | Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations | |
| AU2018302110B2 (en) | Binding proteins 1 | |
| US20260028426A1 (en) | Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus | |
| CN103874710B (zh) | 细胞渗透型抗dna抗体和其抑制dna修复的用途 | |
| JP5828901B2 (ja) | 新規egfr結合分子およびその免疫抱合体 | |
| US10752697B2 (en) | Anti-glypican 3 antibody and pharmaceutical composition containing the same | |
| CN103328505A (zh) | 非拮抗性egfr结合分子及其免疫偶联物 | |
| US20210340279A1 (en) | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators | |
| BR112020013244A2 (pt) | proteínas de fusão de anticorpo citosina-desaminase de domínio único | |
| JP2019512262A (ja) | エンドシアリン結合抗体 | |
| KR20240095534A (ko) | 화학요법 내성 암의 치료 방법에서 사용하기 위한 항체-약물 접합체 | |
| WO2017196764A1 (en) | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses | |
| EP4393515A1 (en) | Anti-cldn-18.2 antibody-drug conjugate and use thereof | |
| WO2025194038A1 (en) | Antibody compositions and methods for targeting extracellular nucleosome proteins | |
| HK40089485B (zh) | 抗cldn-18.2抗体药物偶联物及其用途 | |
| HK40089485A (en) | Anti-cldn-18.2 antibody-drug conjugate and use thereof | |
| WO2026082207A1 (zh) | 抗EGFR和cMET双特异性抗体的抗体药物偶联物 | |
| WO2024259300A2 (en) | Compositions and methods for targeting extracellular dna | |
| HK40111192A (en) | Ph-dependent anti-sulfated glycosaminoglycan antibody and antibody-drug conjugate | |
| TW201711702A (zh) | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180821 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180821 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190619 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190930 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200527 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200824 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201027 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20201202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210217 |